🎥Cecile Riviere-Cazaux, PhD, highlights the role of CSF-based biomarkers in brain tumor trials. Pairing liquid biopsies with tissue biomarkers may optimize use & benchmarking. ➡️https://buff.ly/I2URhgn⬅️ #BTSM #Oncology

🎥Can biomarkers guide T-DXd use in metastatic breast cancer? ⭐ Paolo Tarantino, MD, of @danafarber.bsky.social reports: 🔹More HER2 mRNA/protein → longer benefit 🔹High Topo1 → worse outcomes in HER2⁻ disease ➡️https://buff.ly/G4wnu14 @ascocancer.bsky.social #ASCO25 #BreastCancer #BCSM #ImmunoOnc

🎥 Dr Suneel Kamath from @clevelandclinic.bsky.social addresses cancer research funding disparities: current allocation driven by advocacy. ➡️Proposes burden-based, criteria-driven approach to ensure equity across diseases Watch🔗https://buff.ly/d2uKbEB @ascocancer.bsky.social #ASCO25 #Oncology

🎥Dr Inimfon Jackson from @mdanderson.bsky.social discusses disparities in chemo acceptance: ➡️Greatest in uninsured/publicly insured & Black patients. Advocates trust-building, early risk ID & informed decision support. 🔗 buff.ly/nttGH5r @ascocancer.bsky.social #ASCO25 #Oncology

🎥 @janichinmay.bsky.social explores alcohol’s role in cancer mortality: ➡️Calls for age/geography–stratified analyses & focus on mechanisms incl. microbiome & ICI interaction. Learn more here🔗 buff.ly/zcvqHJd @ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc

🎥 Xiaoqian Nie, PhD, reports Phase I data: ➡️Erythrocyte–antibody conjugates show stronger antitumor activity & better safety vs PD-1 antibodies in checkpoint-refractory cancers. Promising novel IO strategy 🔗 buff.ly/cD7UDXr @ascocancer.bsky.social #ASCO25 #Oncology #ImmunoOnc #CTSM #TrialUpdate

🎥 Dr John Paul Shen (@mdanderson.bsky.social) compares methylation-based tissue-free ctDNA assays vs tissue-reliant approaches. ➡️ Sensitivity varies by tumor site & mutation profile—trials needed to define accuracy in MRD detection. 🔗 buff.ly/cGkX0l2 @ascocancer.bsky.social #ASCO25 #Oncology

🎥 Prof. Francois Doz (@institutcurie.bsky.social) emphasizes precision medicine in pediatric cancer ➡️Trials like iMATRIX Alectinib show promise, but rapid molecular profiling at diagnosis remains a barrier to real-world adoption. 🔗 buff.ly/qJueBU3 @ascocancer.bsky.social #ASCO25 #Oncology #CTSM

🎥 Manmeet Ahluwalia, MD, notes the shift in brain metastasis care: from surgery & WBRT ➡️ targeted therapies & ICIs. Next: combinations with ADCs + ICIs while balancing radiation toxicity. 🔗 buff.ly/Q988SOT @ascocancer.bsky.social #ASCO25 #ImmunoOnc #Oncology #SurgOnc

🎥 Mario Perro, PhD, highlights GRC 65327, a selective Cbl-b inhibitor: 🚀 Boosts T/NK cell activity, restores T cell function & enhances anti–PD-1 responses in solid tumor models. Favorable safety profile supports further study 🔗 buff.ly/hBycSv4 @theaacr.bsky.social #AACR25 #Oncology #ImmunoOnc

🎥 Manas Pustake, MD, highlights disparities in cancer screening access for LGBTQ+ populations vs. non-LGBTQ+ groups in the US, emphasizing the need for targeted interventions: ➡️ buff.ly/5ti0xQr ⬅️ @ascocancer.bsky.social #ASCO25 #Oncology

🎥 Valentina Marulanda Corzo, MD, discusses findings from early-phase trials assessing baseline and follow-up PSMA PET parameters in patients with mCRPC treated with 225Ac-J591: ➡️ buff.ly/777PV9f ⬅️ @ascocancer.bsky.social #ASCO25 #PCSM #UroOnc #UrsoSoMe #TrialUpdate #CTSM

🎥Michael Ong, MD, BSc, FRCPC, highlights the prognostic role of PSA in PC: levels >0.2 may signal worse outcomes, but treatment decisions shouldn’t be based on PSA alone. More research needed, especially for low-PSA patients buff.ly/zZSr2sp @ascocancer.bsky.social #ASCO25 #PCSM #UroOnc #UroSoMe

🎥 Angeles Secord, MD, of @dukecancer.bsky.social shares final Phase II PICCOLO results: mirvetuximab soravtansine shows durable responses & good survival in FRα+ platinum-sensitive ovarian cancer: ➡️https://buff.ly/ysRSWzX⬅️ @ascocancer.bsky.social #ASCO25 #GynOnc #GynSM #TrialUpdate #CTSM

🎥Reena Thomas, MD, PhD, on the future of glioblastoma treatment: ⭐Vaccine-based & stem cell–delivered immune therapies ⭐Combining immune & targeted approaches ⭐Using AI to identify early responders & personalize care ➡️ buff.ly/Kq8dzEE ⬅️ @ascocancer.bsky.social #ASCO25 #BTSM #ImmunoOnc

🎥Prof. Dickon Hayne on the changing landscape of high-risk NMIBC: 💉 BCG + mitomycin remains effective 1L ⚠️ BCG shortages, systemic checkpoint inhibitor drawbacks 🔍 Hope for new intravesical & systemic therapies Watch➡️https://buff.ly/04sbCEd @ascocancer.bsky.social #ASCO25 #Blcsm #ImmunoOnc #CTSM

🎥 Cristina Suárez (@vhio.bsky.social) discusses CONTACT-03 subgroup analysis on cabozantinib ± atezolizumab in advanced #RCC post-immunotherapy at #ASCO25. Key insights for treatment sequencing strategies. 🔗 buff.ly/uix2tBW @ascocancer.bsky.social #KidneyCancer #RCC #GUsm #UroOnc #UroSoMe

🎥Vitaly Margulis, MD, of UT Southwestern Medical Center, Dallas, TX, shares interim ENLIGHTED trial results: padeliporfin VTP is a promising, organ-sparing option for low-grade UTUC: Watch➡️https://buff.ly/sj4WFyF @ascopost.bsky.social #ASCO25 #Blcsm #CTSM #TrialUpdate

🎥 Angeles Secord, MD, from @dukehealth.bsky.social addresses sequencing challenges of ADCs in ovarian cancer. With FDA approvals for mirvetuximab soravtansine and T-DXd, trials are essential for guiding target and payload choices. 🔗https://buff.ly/q23sXHU #ESMOGynae25 #Gyncsm #GynOnc #ImmunoOnc

You're invited to join the Post #ASCO25 Skin Cancer Highlights webinar ON Demand WATCH HERE👉 bit.ly/4eYRegJ hosted by @VJOncology and Featuring expert presentations and in-depth discussions on key abstracts in Skin cancer presented at ASCO 2025.

Clinical challenges and proposed solutions for patients with invasive lobular breast cancer www.annalsofoncology.org/article/S092...

🎯 Advancing prostate cancer care! Valentina Marulanda Corzo (@weillcornell.bsky.social) discusses how PSMA PET parameters can predict response to alpha-targeted therapy 225Ac-J591 in #mCRPC Watch: buff.ly/MAAUxa7 #ProstateCancer #ASCO25 @ascocancer.bsky.social

🎯 Breakthrough in cervical cancer treatment! Domenica Lorusso from discusses how combining immunotherapy + radiotherapy is transforming stage 3 cervical cancer care. KEYNOTE-A18 trial results support this new standard. Watch: buff.ly/TEFMVFl #CervicalCancer

🔬 GI Cancer Sessions from #ASCO25! Leading UCLA Health experts discuss breakthrough trials in GI oncology from #ASCO25 🌟 CHALLENGE (exercise improves colon cancer outcomes) 🌟 ATOMIC (MSI-high immunotherapy) 🌟MATTERHORN (gastric cancer advances) Watch now: buff.ly/Tc81S2w @ASCO #GCsm #GIsm #CRC

🫁 Latest lung cancer insights from leading experts! From immunotherapy breakthroughs to precision medicine advances - catch up on all our weekly podcasts here! 🎧 tinyurl.com/lung-podcasts #LungCancer #Oncology #Podcast

How we treat patients with advanced #BTC #CCA from #ESMOGI25. Expert centers, MDTs, molecular profiling, chemo-immunotherapy, and targeted agents @vjoncology.bsky.social

NEW #VJOncoAlert Journal Club with @oncoalert.bsky.social Tackling "unresectable" high-risk stage III #NSCLC with Biagio Ricciuti from @danafarbernews.bsky.social Watch 📹: tinyurl.com/ev5usd29 Read 🔖: tinyurl.com/3jafzs23 #LungCancer #LCsm

🎥Julien Edeline, MD, PhD, shares CHIEF cohort data in HCC: 2L access drops post-IO 1L, but TKI outcomes stay consistent. IO rechallenge looks promising—though selection bias may play a role. 🔗 buff.ly/uhfMblQ @myesmo.bsky.social #ESMOGI25 #CTSM

🎥 @lorenzarimassa.bsky.social of HUNIMED discusses expert care & molecular testing in advanced biliary tract cancer. 1L chemo + IO (cis/gem + durva/pembro); 2L guided by biomarkers. From #ESMOGI25 Congress. Watch: buff.ly/nZSaehg @myesmo.bsky.social #Oncology #ImmunoOnc

🎥Andrew Parsonson of Macquarie University shares updated Phase I/II results for B7H3-targeting ADC DB-1311 in heavily pretreated CRPC Watch ➡️ buff.ly/gyAysrg @ascocancer.bsky.social #ASCO25 #PCSM #UroOnc

🎥 Zeynep Eroglu, MD (@moffittnews.bsky.social), shares SWOG S2000 results: triplet therapy beats ipi+nivo for BRAFV600-mutant melanoma brain mets, with better PFS & response rates. Watch here: buff.ly/8Aa54tT #ASCO25 #Melanoma #Immunotherapy #TrialUpdate

🎥Gene-level results from TALAPRO-2: Talazoparib + enzalutamide improved rPFS & OS in mCRPC Stefanie Zschaebitz (@uniheidelberg.bsky.social) shares more from #ASCO25 ➡️https://buff.ly/08HFZr9⬅️ @ascocancer.bsky.social #CTSM #PCSM #ProstateCancer

🎧 Listen to this week on the VJOncology podcast: key updates in CAR-T & cellular therapies for brain tumors, incl. B7H3 CAR-T trials, dendritic cell therapy & new strategies for glioblastoma. Expert insights from top voices in the field! ➡️https://buff.ly/07VYXFB #BTSM #ImmunoOncology #CART

🎥Sarah Lochrin of @mskcancercenter.bsky.social shares interim Phase II C-IT Neo trial results Watch ➡️https://buff.ly/DawY2Ju #ASCO25 #Melsm #Skcsm #CTSM #TrialUpdate #ImmunoOnc

Glad to chair the @vjoncology.bsky.social webinar on #GI cancer and discuss the most important data presented at #ASCO and #ESMOGI with experts in the field! Please see below the agenda and join us!

🚨 NEW #VJOncoAlert Journal Club episode from @vjoncology.bsky.social and @oncoalert.bsky.social 🚨 @silkegillessen.bsky.social discusses the addition of metformin to the SOC in mHSPC in the STAMPEDE trial! 📷Watch here: tinyurl.com/4knvf3ka 📔Read here: tinyurl.com/5fbjnsk3

🎥Results from PDIGREE: ipi + nivo in mccRCC shows consistent safety & early CRs in a diverse U.S. population @tiansterzhangmd.bsky.social shares insights from #ASCO25 ➡️https://buff.ly/o2oUojf⬅️ @ASCO #kcsm #UroOnc #UroSoMe #CTSM #TrialUpdate #ImmunoOnc

Expert-led Post-#ASCO2025 & #ESMOGI2025 Highlights webinars 💻📍 The #GICancer session will be chaired by @lorenzarimassa.bsky.social & moderated by Richard Kim, Filippo Pietrantonio & Efrat Dotan AGENDA 👉 buff.ly/NtN20KG REGISTER 👉 buff.ly/4Z7VyTB

🎥Paola Zagami of European Institute of Oncology IRCSS discusses CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer, a key strategy to reduce treatment interruptions and improve outcomes. ➡️ buff.ly/DDkTMtU%E2%A... @ascocancer.bsky.social #ASCO25 #BreastCancer #bcsm

🎥Swati Kulkarni (Northwestern University Feinberg School of Medicine) discusses CE/BZA as a potential option for managing menopausal symptoms in women at higher breast cancer risk ➡️ buff.ly/5A3J565 @ascocancer.bsky.social #ASCO25 #BreastCancer #bcsm

🎥Ilana Cass, MD, of @dartmouthhealth.bsky.social highlights RUBY trial data: dostarlimab + chemo improves time to next treatment across age groups in advanced/recurrent endometrial cancer, incl. MSS patients ➡️ buff.ly/nFPKNXl @myesmo.bsky.social #GynOnc #GyncSM #ImmunoOnc #CTSM #TrialUpdate

🎥@ehbent.bsky.social of @mskcancercenter.bsky.social explores how biomarkers may guide use of metastasis-directed radiation ± hormonal therapy in oligometastatic prostate cancer, though clinical traits still lead. Watch ➡️ buff.ly/pkhx0zl @ascocancer.bsky.social #ASCO25 #UroOnc #UroSoMe #PCSM

⏱️Delaying interval surgery after 6 cycles of NAC in advanced ovarian cancer doesn't worsen OS or PFS, per new data shared by Prof. Christina Fotopoulou at #ESMOGynae25. Timing may depend more on clinical context than chemo cycle ➡️ buff.ly/ReORMEN @myesmo.bsky.social #GynOnc #GyncSM

🎥Stefanie Zschaebitz, MD, of @uniheidelberg.bsky.social shares TALAPRO-2 gene-level data in mCRPC: talazoparib + enzalutamide improved rPFS/OS in HRR-deficient tumors: 🔗 ow.ly/ook950WiqkB @ascocancer.bsky.social #ASCO25 #PCsm #mCRPC #HRR #CTSM #TrialUpdate

🎥 Angela Jia, MD, PhD, shares updates in high-risk localized #ProstateCancer: CAN-2409 + EBRT improved DFS, and a multimodal AI model from STAMPEDE may guide AR pathway inhibitor use to avoid overtreatment. 🔗 buff.ly/Z8f6Qry @ascocancer.bsky.social #ASCO25 #UroOnc #UroSoMe #CTSM

🎥 Marina De Brot, MD, PhD, discusses AI in pathology at #ASCO25 - from current applications improving HER2 IHC accuracy to access challenges. AI tools are enhancing diagnostic precision in clinical practice. 🔗 buff.ly/EQoKKum @ascocancer.bsky.social #AIinMedicine #Pathology #BCsm #BreastCancer

🎥@sdanson1.bsky.social of @sheffielduni.bsky.social discusses latest #melanoma updates from #ASCO25, including DREAMseq trial results on nivolumab + ipilimumab in BRAFV600-mutant metastatic melanoma. 🔗 buff.ly/V1sB5DB @ASCO #Melanoma #Immunotherapy #Melsm #Sksm

🎥 At #ASCO25 Joshua Sabari, MD, discusses HER2-directed therapies in #NSCLC, highlighting zongertinib's promising patient-reported outcomes from the Beamion LUNG-1 trial: 🔗 buff.ly/bJXuOeA @ascocancer.bsky.social #LungCancer #HER2 #LCsm

🎥Christian Singer, MD, of @meduniwien.ac.at discusses post-neoadjuvant challenges in #TNBC. For patients w/o (near-)pCR, especially non-BRCA carriers, treatment options remain limited, & more research is urgently needed: 🔗 buff.ly/w2PIFg9 @ascocancer.bsky.social #ASCO25 #BreastCancer

🎥 Jalid Sehouli, MD, discusses a post-hoc analysis of SIENDO: selinexor as maintenance in TP53 WT endometrial cancer showed consistent PFS benefit across subgroups. Watch here ➡️ ow.ly/aTXv50WhTZx #ASCO25 #GynOnc #Gyncsm #EndometrialCancer